Analysis of 1,074 CRC patients from the QUASAR 2 trial (Kerr et al, 2016) proved that high MERTK expression is a prognostic marker for poor survival, defining this receptor tyrosine kinase as an attractive potential target for therapeutic intervention. The gene discussed is MERTK; the disease is colorectal carcinoma.